Brain AVMs are congenital vascular lesions consisting of direct artery-to-vein shunts without an intervening capillary bed. They are a major cause of hemorrhagic stroke in young adults, accounting for 25% of hemorrhagic strokes in adults <50 years and up to 70% in children <19 years. [1] Rupture carries 10–30% mortality, and up to 40% of survivors die or remain functionally impaired within 1 year. [1-2] The following figure illustrates the Spetzler-Martin grading system and treatment modalities:
1. History
- Onset: Sudden, severe headache ("thunderclap" or "worst headache of life"), often with acute focal neurological deficit
- Symptom characterization: Headache, nausea/vomiting, altered consciousness, seizure, visual changes, speech difficulty, limb weakness
- Timing/triggers: Typically spontaneous; may occur during exertion or Valsalva, though no consistent trigger is established
- Progression: Rapid neurological deterioration suggests hematoma expansion or hydrocephalus
- Prior symptoms: ~20–25% of AVMs present initially with seizures; 15% with headaches; <5% with progressive focal deficits [4]
- Important negatives: No trauma history (distinguishes from traumatic ICH); no preceding anticoagulant use; no known coagulopathy
2. Alarm Features
- GCS ≤8 — indicates severe hemorrhage, need for airway protection
- Rapidly declining level of consciousness (herniation)
- Fixed, dilated pupil(s) — uncal herniation
- Cushing triad (hypertension, bradycardia, irregular respirations)
- New-onset seizures with postictal obtundation
- Signs of intraventricular hemorrhage (IVH): acute hydrocephalus, upward gaze palsy
- Hemorrhage in young patient (<40 years) without hypertension — high suspicion for underlying vascular malformation [4-5]
3. Medications
- Acute BP management: IV nicardipine or labetalol for SBP lowering; target SBP 130–140 mmHg per INTERACT-2/INTERACT-3 data; avoid SBP <130 mmHg (associated with harm) [6]
- Anticonvulsants: Initiate only if clinical seizures occur (levetiracetam preferred; avoid phenytoin if possible due to side-effect profile) [7]
- Reverse coagulopathy: Vitamin K + 4-factor PCC for warfarin; idarucizumab for dabigatran; andexanet alfa for factor Xa inhibitors; platelet transfusion if thrombocytopenic
- DVT prophylaxis: Mechanical (SCDs) initially; pharmacologic DVT prophylaxis timing is individualized [7]
- Medications to AVOID:
- Anticoagulants and antiplatelets in the acute phase
- Aspirin and NSAIDs (increased bleeding risk)
- Venous vasodilators (nitroprusside, nitroglycerin) — may raise ICP [6]
4. Diet
- NPO in the acute setting (potential for emergent surgery or intubation)
- Once stabilized and airway secured, advance diet as tolerated
- Long-term: no specific dietary triggers for AVM rupture; general cardiovascular-healthy diet is reasonable
5. Review of Systems
- Neurological: Headache severity/onset, vision changes, speech difficulty, weakness/numbness, seizure activity, altered mentation
- Cardiovascular: History of hypertension (modifiable risk factor for ICH) [8-9]
- Hematologic: Bleeding history, easy bruising, anticoagulant/antiplatelet use
- Constitutional: Epistaxis, telangiectasias (screen for hereditary hemorrhagic telangiectasia — 10–20% of HHT patients have brain AVMs) [10]
6. Collateral History and Family History
- Collateral: Witnesses to onset (time of symptom onset is critical), baseline functional status, medication list (especially anticoagulants), last known normal time
- Family history:
- Hereditary hemorrhagic telangiectasia (HHT/Osler-Weber-Rendu): Autosomal dominant; mutations in ENG, ACVRL1, SMAD4 — associated with brain AVMs [10-11]
- Family history of hemorrhagic stroke, aneurysms, or vascular malformations
- Social context: Smoking (associated with higher mortality in ruptured deep-seated AVMs); alcohol and drug use (especially sympathomimetics) [12]
7. Risk Factors
For AVM rupture
- Prior hemorrhage — strongest predictor; annual re-rupture risk ~6% in the first year post-hemorrhage, then returns toward baseline 2–4% [2][5]
- Deep venous drainage (exclusive) [5][13]
- Deep/periventricular location [5][14]
- Small nidus size (paradoxically higher rupture risk) [13-14]
- Intranidal or feeding artery aneurysms [13][15]
- Single draining vein [13-14]
- Fewer draining veins and smaller arterial feeders [14]
- Male sex showed predominance in the rupture group in one study [14]
- Hypertension [9]
8. Differential Diagnosis
- Ruptured cerebral aneurysm (SAH pattern, often perimesencephalic or basal cistern blood)
- Hypertensive intracerebral hemorrhage (basal ganglia, thalamus, pons — typical locations; older patient with HTN)
- Hemorrhagic transformation of ischemic stroke (preceding ischemic symptoms, territory-specific)
- Cerebral cavernous malformation hemorrhage (typically smaller bleeds, lower morbidity) [5]
- Dural arteriovenous fistula rupture [5]
- Cerebral venous sinus thrombosis with hemorrhagic infarction
- Hemorrhagic brain tumor (glioblastoma, metastasis — subacute onset, surrounding edema)
- Cerebral amyloid angiopathy (lobar hemorrhage in elderly, recurrent)
- Coagulopathy-related hemorrhage
- Mycotic aneurysm (endocarditis, distal vessel location) [5]
9. Past Medical History
- Prior seizures or headaches (may indicate previously undiagnosed AVM)
- Previous intracranial hemorrhage
- Known vascular malformations
- HHT or family syndromes
- Hypertension
- Coagulopathies or anticoagulant use
- Prior neurosurgical procedures
- Cardiac conditions (endocarditis → mycotic aneurysm)
10. Physical Exam
- Vitals: Hypertension is extremely common; monitor for Cushing triad
- Neurological exam:
- GCS assessment (serial)
- Pupil size and reactivity (asymmetry → herniation)
- Focal motor deficits (hemiparesis/hemiplegia localizes hemorrhage)
- Speech/language assessment (aphasia if dominant hemisphere)
- Cranial nerve palsies
- Cerebellar signs (if posterior fossa AVM)
- Meningismus (if subarachnoid extension)
- Skin: Telangiectasias on lips, tongue, fingertips (HHT screening)
- Fundoscopy: Papilledema (raised ICP), subhyaloid hemorrhage (Terson syndrome)
- Auscultation: Cranial bruit (rare but classic for large AVMs)
11. Lab Studies
- CBC with platelets
- Coagulation panel: PT/INR, aPTT, fibrinogen
- BMP (electrolytes, glucose, renal function)
- Type and screen/crossmatch
- Troponin (neurogenic cardiac injury)
- Hepatic function panel (if coagulopathy suspected)
- Toxicology screen (sympathomimetics can precipitate hemorrhage)
- Blood glucose — hyperglycemia worsens outcomes; target normoglycemia [7]
- ABG/VBG if intubated
12. Imaging
- First-line: Non-contrast CT head — identifies acute hemorrhage, location, volume, hydrocephalus, midline shift
- CT angiography (CTA): Rapid identification of underlying vascular malformation; good sensitivity for AVM nidus, feeding arteries, and draining veins [16]
- MRI/MRA: Very sensitive for AVM — shows characteristic flow voids on T1/T2; hemosiderin staining suggests prior hemorrhage; provides critical anatomic detail for surgical planning [4]
- Gold standard: Digital subtraction angiography (DSA) — defines arterial feeders, nidus architecture, venous drainage, intranidal aneurysms, and flow dynamics; essential for treatment planning [4][15]
- When imaging is unnecessary: CT is always indicated in acute presentation; DSA may be deferred if patient is unstable and requires emergent surgery
Key imaging findings suggesting higher rupture risk: Intranidal aneurysm, deep venous drainage, deep location, venous outflow obstruction [10]
13. Special Tests
- Spetzler-Martin (SM) Grading Scale[5][13][16]
- Lawton-Young Supplementary Scale: Adds patient age, hemorrhagic presentation, and nidus compactness to enhance SM predictive power [7]
- RAGS (Ruptured AVM Grading Scale): Extension of Hunt-Hess incorporating age, deep venous drainage, and eloquence; AUROC >0.80 for predicting outcome after rupture [17]
- ABC/2 formula for hematoma volume estimation on CT
14. ECG
- Obtain ECG on all patients — neurogenic cardiac changes are common with ICH
- Findings to watch for:
- ST-segment changes, T-wave inversions (neurogenic stunned myocardium)
- QTc prolongation
- Arrhythmias (atrial fibrillation, ventricular ectopy)
- Continuous telemetry monitoring in the ICU
15. Assessment
- Brain AVMs are congenital high-flow vascular lesions that most commonly present in patients <40 years [4][7]
- >50% present with hemorrhage as the initial manifestation [4]
- Rupture-associated mortality: 10–30%; of survivors, ~25% have no deficit, 30% mild-moderate deficits, 45% severe deficits [2-3]
- At 3 months post-hemorrhage, ~20% of initial survivors have died, and one-third remain moderately disabled [3]
- Re-rupture risk is ~6% in the first year, then returns to baseline 2–4%/year [2][5]
- Severity stratification depends on GCS, hematoma volume, location, presence of IVH, and SM grade
16. Treatment Plan
Initial Stabilization (ED)
- ABCs: Intubate for GCS ≤8 or inability to protect airway
- Blood pressure: IV nicardipine or labetalol; target SBP 130–140 mmHg; avoid SBP <130 mmHg [6]
- Reverse coagulopathy immediately
- Seizure management: Treat clinical seizures with benzodiazepines acutely, then levetiracetam; routine prophylaxis is not universally recommended [7]
- ICP management: Head of bed 30°, osmotherapy (mannitol 20% 1 g/kg or hypertonic saline 23.4% 30 mL), avoid hyperthermia, target normoglycemia
- Emergent neurosurgical consultation
Surgical/Interventional Management: [5][7]
- Emergent hematoma evacuation for life-threatening mass effect regardless of AVM grade
- Small, superficial AVMs (SM grade I–II) can be resected during emergency surgery
- Larger/deep AVMs: Defer definitive resection 2–6 weeks to allow brain swelling to resolve and better delineate the AVM [2][7]
- Targeted embolization of intranidal/perinidal aneurysms to reduce re-rupture risk in the interim [7][15]
- Stereotactic radiosurgery (SRS): Best for small (<3 cm), deep, eloquent-location AVMs; obliteration takes ~3 years; persistent hemorrhage risk until obliteration [3][7]
- Multimodal therapy (embolization + surgery ± SRS) is common for complex lesions [18]
EVD placement for acute hydrocephalus [7]
17. Disposition
- All ruptured AVMs require admission — preferably to a dedicated neurological ICU [7]
- Transfer to a comprehensive stroke center or facility with neurosurgery, neurointerventional radiology, and neurointensive care if not available [7]
- Admission criteria:
- Any intracranial hemorrhage from AVM rupture
- Need for ICP monitoring, EVD, or invasive hemodynamic monitoring
- Post-operative monitoring after hematoma evacuation or AVM resection
- Specialist consultation triggers:
- Neurosurgery (all cases)
- Neurointerventional radiology (for embolization planning)
- Neurology (seizure management, medical optimization)
18. Follow-Up / Return Precautions
- Definitive treatment planning occurs 2–6 weeks post-hemorrhage after brain swelling resolves [2][7]
- Repeat imaging (MRI/MRA and DSA) to delineate residual AVM anatomy before definitive treatment [4]
- Long-term follow-up after treatment:
- Post-surgical: MRI/MRA and DSA to confirm complete obliteration
- Post-radiosurgery: Annual MRI for ≥3 years until obliteration confirmed; persistent hemorrhage risk until obliteration [7][10]
- Post-embolization: Follow-up angiography to assess residual nidus
- Return precautions (for patients discharged after stabilization/treatment):
- Expected recovery: Highly variable depending on hemorrhage location/volume and SM grade; rehabilitation (PT/OT/speech) is often required
- Smoking cessation should be strongly encouraged — associated with higher mortality in ruptured deep-seated AVMs [12]
- Genetic counseling if HHT is suspected (screen family members) [11]
References
1. Risk of Future Hemorrhage From Unruptured Brain Arteriovenous Malformations. — Kim H, Nelson J, McCulloch CE, et al. JAMA Neurology. 2025.
2. Management of Ruptured Brain Arteriovenous Malformations. — Zacharia BE, Vaughan KA, Jacoby A, et al. Current Atherosclerosis Reports. 2012.
3. Arteriovenous Malformations of the Brain. — Solomon RA, Connolly ES. The New England Journal of Medicine. 2017.
4. Recommendations for the Management of Intracranial Arteriovenous Malformations: A Statement for Healthcare Professionals From a Special Writing Group of the Stroke Council, American Stroke Association. — Ogilvy CS, Stieg PE, Awad I, et al. Circulation. 2001.
5. Cerebral Intraparenchymal Hemorrhage: A Review. — Gross BA, Jankowitz BT, Friedlander RM. The Journal of the American Medical Association. 2019.
6. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. — Jones DW, Ferdinand KC, Taler SJ, et al. Journal of the American College of Cardiology. 2025.
7. Management of Brain Arteriovenous Malformations: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. — Derdeyn CP, Zipfel GJ, Albuquerque FC, et al. Stroke. 2017.
8. Primary and Secondary Prevention Of Ischemic Stroke and Cerebral Hemorrhage: JACC Focus Seminar. — Diener HC, Hankey GJ. Journal of the American College of Cardiology. 2020.
9. Arteriovenous Malformations. — Fleetwood IG, Steinberg GK. Lancet. 2002.
10. ACR Appropriateness Criteria® Cerebrovascular Diseases-Aneurysm, Vascular Malformation, and Subarachnoid Hemorrhage. — Ledbetter LN, Burns J, Shih RY, et al. Journal of the American College of Radiology : JACR. 2021.
11. Arteriovenous Malformations (AVMs): Molecular Pathogenesis, Clinical Features, and Emerging Therapeutic Strategies. — Le N, Li Y, Walker G, et al. Biomolecules. 2025.
12. Management and Outcome Predictors of Patients With Ruptured Deep-Seated Brain Arteriovenous Malformations. — Sattari SA, Yang W, Feghali J, et al. Journal of Neurosurgery. 2024.
13. AHA Scientific Statement: Recommendations for the Management of Intracranial Arteriovenous Malformations: A Statement for Healthcare Professionals From a Special Writing Group of the Stroke Council, American Stroke Association. — Ogilvy CS, Stieg PE, Awad I, et al. Stroke. 2001.
14. Relationship of Blood Flow, Angioarchitecture, and Rupture in Cerebral Arteriovenous Malformations. — McGuire LS, Abou-Mrad T, Theiss P, et al. Journal of Neurosurgery. 2025.
15. Targeted Endovascular Treatment for Ruptured Brain Arteriovenous Malformations. — Hou K, Xu K, Chen X, et al. Neurosurgical Review. 2020.
16. Interventions for Treating Brain Arteriovenous Malformations in Adults. — Zuurbier SM, Al-Shahi Salman R. The Cochrane Database of Systematic Reviews. 2019.
17. The Ruptured Arteriovenous Malformation Grading Scale (RAGS): An Extension of the Hunt and Hess Scale to Predict Clinical Outcome for Patients With Ruptured Brain Arteriovenous Malformations. — Silva MA, Lai PMR, Du R, Aziz-Sultan MA, Patel NJ. Neurosurgery. 2020.
18. Indications for the Performance of Intracranial Endovascular Neurointerventional Procedures: A Scientific Statement From the American Heart Association. — Eskey CJ, Meyers PM, Nguyen TN, et al. Circulation. 2018.